Protego Biopharma Appoints John M. Maraganore, Ph.D., to Board of Directors
Dr. Maraganore brings more than three decades of experience leading discovery, development and commercialization of groundbreaking medicines Founding CEO of Alnylam Pharmaceuticals led company through global approval and commercialization of its first five RNAi medicines SAN DIEGO, Calif., March 3, 2026 — Protego Biopharma, Inc., a clinical-stage biotechnology company dedicated to pioneering first-in-class small […]
Protego Biopharma Raises $130 Million Oversubscribed Series B Financing to Advance First-in-Class AL Amyloidosis Program into Pivotal Study
– Financing led by Novartis Venture Fund and Forbion, with new investment from Omega Funds, Droia Ventures, YK Bioventures, and Digitalis Ventures – Renewed backing from Vida Ventures, MPM BioImpact, Lightspeed Venture Partners, and Scripps Research SAN DIEGO, Calif., Dec. 1, 2025 — Protego Biopharma, Inc., a clinical-stage biotechnology company dedicated to pioneering […]
Protego Biopharma Raises $51 Million Series A Financing to Advance the Treatment of Protein Misfolding Diseases
November 17, 2021 Lightspeed Venture Partners and Vida Ventures join seed investor MPM Capital to lead Series A financing Protego’s proprietary technology platforms based on pioneering work from the Scripps Research labs of Dr.s Jeffery W. Kelly and R. Luke Wiseman SAN DIEGO, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) — Protego Biopharma, Inc., a […]